BiotechTubeBiotechTube
Home/Arcutis Biotherapeutics/Mas Matsuda
MM

Mas Matsuda

Executive Vice President and Chief Legal Officer

Arcutis Biotherapeutics

Therapeutic Areas

DermatologyImmunology

Arcutis Biotherapeutics Pipeline

DrugIndicationPhase
ZORYVE (roflumilast) Cream 0.3%Plaque Psoriasis (Adults & Adolescents)Approved
ZORYVE (roflumilast) Cream 0.15%Atopic Dermatitis (Adults & Adolescents)Approved
ZORYVE (roflumilast) Cream 0.05%Atopic Dermatitis (Children 2-5 years)Approved
ZORYVE (roflumilast) Foam 0.3%Seborrheic DermatitisApproved
ARQ-234Atopic DermatitisPreclinical/Phase 1